FDA Grants Roche’s Giant Cell Arteritis Drug Actemra Breakthrough Status The U.S. Food and Drug Administration granted breakthrough therapy designation status to Actemra, a giant cell arteritis drug by Roche. In 2015, the company also received the designation for their systemic sclerosis research. by Livia Rusu